MedTrace Logo

Mecamylamine for Autonomic Dysreflexia Prophylaxis

NCT03914677 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-10-07

No results posted yet for this study

Summary

This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Mecamylamine Oral Tablet

nicotinic antagonist (ganglionic blocker)

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • EDWARD C NIESHOFF, MD · Wayne State University

Study Design

Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-13
Primary Completion
2020-03-17
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914677 on ClinicalTrials.gov